ABUS Club Newsletter
Web version

Elevating Personalized Breast Care
Integrating ABUS for Women with Dense Breasts Provides Significant Economic Savings
Supplemental screening for women with dense breasts is proven to find more cancers but is it economically sustainable?1 A recent study in Italy led by Dr. Gianfranco Scaperrotta, Head of the Breast Imaging Unit of the Foundation IRCCS National Cancer Institute of Milan, says yes.

"Adding hand-held breast ultrasound to mammography is a method that has already proven to be able to double the detection rate in breast screening, but there are concerns about false positives, user variability and unsustainable costs. Therefore, starting from these considerations, we decided to approach these concerns with a lean and fast system like Automated Breast Ultrasound (ABUS), which offers high diagnostic sensitivity, reproducible and far less operator variability," said Dr. Scaperrotta.
Dr. Gianfranco Scaperrotta
Dr. Gianfranco Scaperrotta,
Head of the Breast Imaging Unit of the Foundation IRCCS National Cancer Institute of Milan
The study analyzed the Italian NHS perspective and healthcare expenditure over three years.

The model looked at three breast screening pathways, considering both the screening and diagnosis phase and the cancer care and treatment phase of the breast care pathway:
1. Using mammography alone
2. Using both associated mammography and traditional hand-held ultrasound for dense breasts
3. Using a path combining mammography and ABUS for dense breasts
Researchers from the Foundation IRCCS National Cancer Institute of Milan used Invenia™ ABUS to conduct the economic study. The study found that beyond the proven clinical outcomes of adding ABUS to mammography, there were also economic benefits, with savings of over 50 million euros for the Italian National Health Service when compared to using mammography screening only. A prior research study has shown a 57% increase in invasive cancer detection rate when Invenia ABUS was added to mammography by keeping a stable recall rate of 2.3%.2

The study found that the addition of ABUS initially led to an increase in system expenditures in the screening phase; however, the economic savings were realized in the later phases for patients undergoing treatment for breast cancer.

"The result obtained is very interesting because it shows that if ABUS detects small invasive early-stage cancers while also having lower and sustainable costs compared to traditional hand-held ultrasound, it allows a strong repercussion on the costs of medical treatment, particularly surgical, with significant economic savings for the Italian NHS, especially for the first year of diagnosis," Dr. Scaperrotta said.

Moving forward, this study in Italy is hoping to provide a model for the future of personalized breast care with important clinical and economic outcomes.
The Importance of Continuous Education About Breast Density  
Dr. Athina Vourtsis discusses the important mission and work that DenseBreast-Info.org/Europe is doing to enable early cancer detection for women with dense breast tissue.  
Athina Vourtsis, MD, PhD
Athina Vourtsis, MD, PhD,
DenseBreast-info.org European Liaison, Director and Founder of Diagnostic Mammography Center, Athens, Greece
Comprehensive Breast Cancer Awareness Month Activities for ABUS
Our breast care solutions are designed with the same goal: to provide the most precise, personalized care in the industry in a safe, efficient and patient-centric manner.

Register today for our Webinars @ EUSOBI 2020 to explore the role of Automated Breast Ultrasound.

Additionally learn from Prof. Mathias Goyen, CMO of GE Healthcare Europe, about our vision of Personalized Breast Care focusing on a multi-modality approach highlighting the latest innovations and scientific evidence.
Dr. Jonathan James TUESDAY, OCTOBER 6TH – 5PM CEST
Introduction to Reading CESM Images: Clinical Cases
Dr. Jonathan James – Nottingam Breast Institute (UK)
Dr. Anat Kornecki MONDAY, OCTOBER 12TH – 5PM CEST
Alternative to MRI: from Diagnosis to Biopsy
Dr. Anat Kornecki – Western University, London, Ontario (CAN)
Dr. Athina Vourtsis, MD, PhD WEDNESDAY, OCTOBER 14TH – 5PM CEST
Personalized Breast Care, Exploiting the Latest Innovations from 3D ABUS to Handheld Ultrasound
Dr. Athina Vourtsis, MD, PhD – Director & Founder of Diagnostic Mammography Center, Athens, Greece – Founding President of the Hellenic Breast Imaging Society – European Liaison and Member of the Medical Advisory Board of DenseBreast-Info.org
Prof. Emeritus Laszlo Tabar, M.D., F.A.C.R. THURSDAY, OCTOBER 22ND – 5PM CEST
3D Automated Breast Ultrasound as an Innovative and Effective Screening Solution for Women with Dense Breasts
Prof. Emeritus László Tabár, MD, FACR (Hon)
Role of CEUS Imaging in Breast Carcinoma Diagnosis and Follow-up
Dr. Eugen Divjak, MD (Zagreb, Croatia)
Prof. Dr. Mathias Goyen THURSDAY, OCTOBER 29TH – 5PM CEST
Leveraging Technology Innovations to Personalize Breast Care
Prof. Dr. Mathias Goyen, MD – Chief Medical Officer, GE Healthcare Europe
  Join our LIVESTREAM – The Clinical Usage of Automated Breast Ultrasound
Breast Center Caritaskrankenhaus
St. Josef Regensburg
Learn from PD Dr. Stephan Seitz about the clinical indications and the effective usage of ABUS combined with an interesting clinical case review.

During the Livestream a chat function will be available for interactive discussions!

Language: German
Date: Thursday, October 29, 12:30 – 1:15pm (CEST)
PD Dr. Stephan Seitz
PD Dr. Stephan Seitz,
Coordinator of Breast Center, Deputy Director of Obstetrics and Gynecology Clinic, Teaching Hospital University Regensburg
  Interactive Conversations with Prof. László Tabár, MD, FACR (Hon)
This lively, monthly global webcast series is for passionate breast imaging professionals. Prof. Tabár will share topical lectures, review multimodality clinical case studies and answer your questions in real-time.

Professor László Tabár is a visionary physician, researcher, and consummate educator. He introduced the world to breast cancer screening – and continues to advocate and educate on the benefits of early cancer detection.
Prof. Emeritus Laszlo Tabar
  Invenia ABUS 2.0 is part of the suite of personalized breast cares solutions from GE Healthcare. To learn more please click on the boxes below:
Learn More
View Video
1. Article access on 7/15/2020: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872003/
2. Article accessed on 7/15/2020: https://www.sciencedirect.com/science/article/pii/S0720048X16301760

© 2020 General Electric Company. GE, the GE Monogram and Invenia are trademarks of General Electric Company.

 Do not reply to this email as it was sent from an unmonitored account.
Unsubscribe from the Breaking News.
Reset your password.
Contact auntminnieeurope.com support.
AuntMinnieEurope.com Privacy Policy
Email sent to: .

AuntMinnieEurope.com, 1350 North Kolb Road, Suite 215, Tucson, AZ 85715 USA
+1 520-298-1000